After decades of relative stagnation in treatment options, 2017 ushered in the approval of several new therapies for acute myeloid leukemia (AML). With those new therapies comes the hope that AML may be ripe for more precise, rational, and efficacious treatments specific to molecular subtype or biologic mechanism. And yet, in 2018, how and when to test for genetic mutations, when to treat with novel agents, and whether a given patient will benefit from classical induction therapy all remain thorny questions without straightforward answers. This session will focus on how to appropriately utilize next generation sequencing and other molecular testing to characterize AML, how to incorporate novel therapies, and what to expect from traditional chemotherapeutic strategies given our understanding about disease heterogeneity.
Dr. Elizabeth Griffiths will review the role of mutational profiling in helping to define disease biology in AML at diagnosis and relapse. She will describe how mutational data are helping to inform clinical prognosis and provide opportunities for rational targeted therapeutics. Dr. Griffiths will further review which mutational events might be used to alter the approach to patient care by distinguishing those patients likely to benefit from traditional consolidation from those more suitable for inclusion in clinical trials or upfront allogeneic transplantation.
Dr. Daniel Pollyea will discuss what approaches to AML may look like in the near future with newer, molecularly defined therapies that may complement, or replace, intensive induction chemotherapy. He will describe which agents are most promising, when and how they may be used, and outline an approach to AML informed by disease biology rather than convention.
Dr. Laura Michaelis will discuss the role that classical cytotoxic therapy still plays in the treatment of newly diagnosed and relapsed patients with AML. She will summarize what can be expected from cytotoxic induction regimens in patients with good risk and intermediate risk disease and update the audience on options for patients with adverse risk cytogenetic and molecular features. Dr. Michaelis will touch on new developments in relapsed/refractory disease and, finally, will outline a reasonable approach to choosing which patients are least likely to benefit from cytotoxic therapy and should be targeted for clinical trials of less-intensive options.
Elizabeth Griffiths, MD
Daniel Pollyea, MD
Laura Michaelis, MD
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members